Leerink Partners Maintains Market Perform on 10x Genomics, Raises Price Target to $90
Leerink Partners analyst Mike Kratky maintains 10x Genomics (NASDAQ:TXG) with a Market Perform and raises the price target from $40 to $90.
Share
Why It Matters
An expert analyst raised her price goal for 10x Genomics from $40 to $90. She thinks the company is doing okay, not great or bad right now.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.